ATH.AX

Compare

No price history available for this symbol yet.

Fair-value model

Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.

Years of analysisAssumption entries

Analyst estimates unavailable for this ticker.

Held by

portfolios on TandT

Bookmarked by

users

Avg position size

—

of holders' portfolios

13F filers

institutions

Sector

Biotechnology

Analyst estimates (consensus)

Year	Est. revenue	Growth	Est. EPS	EPS range	Fwd P/E	# Analysts
2027	$2M	-30.0%	$-0.03	$-0.03–$-0.03	—	1
2028	$5M	+125.7%	$-0.04	$-0.04–$-0.04	—	3
2029	$7M	+41.5%	$-0.05	$-0.05–$-0.05	—	3
2030	$19M	+176.6%	$-0.03	$-0.03–$-0.03	—	1

Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep

Earnings surprises

Beat consensus in 4 of the last 8 reported quarters

Reported	Est. EPS	Actual	Surprise
2026-08-28	$-0.01	$-0.01	+56.7%
2026-02-25	$-0.03	$-0.04	-56.5%
2025-08-28	$-0.07	$-0.04	+42.3%
2025-02-28	$-0.09	$-0.07	+18.2%
2025-02-03	$-0.01	$-0.10	-1150.0%
2024-02-28	$-0.02	$-0.13	-712.5%
2023-08-31	$-0.02	$-0.12	-566.7%
2023-02-28	$-0.28

DCF fair valuemodel estimate

Intrinsic value

$0.21

Price

$0.42

Implied downside

-52%

Peer comparison

Symbol	Price	Today	Mkt cap	P/E
ATH.AXAlterity Therapeutics Limited	$0.42	-5.56%	$92M	—
ACW.AXActinogen Medical Limited	$0.06	-5.00%	$212M	—
ALA.AXArovella Therapeutics Limited	$0.06	-1.67%	$71M	—
BIO.AXBiome Australia Limited	$0.37	+4.23%	$84M	—
EZZ.AXEZZ Life Science Holdings Limited	$0.43

Alterity Therapeutics Limited

Based in Melbourne, Australia, Alterity Therapeutics Limited, founded in 1997, is dedicated to the discovery and advancement of treatments for neurological conditions such as Alzheimer's, Huntington's, and Parkinson's diseases, among others. The company's primary drug candidate, ATH434, has successfully navigated Phase I clinical trials for Parkinson's disease. Additionally, it is progressing PBT2, an investigational compound for Alzheimer's disease that has completed Phase 2a clinical trials. The firm, previously known as Prana Biotechnology Limited, adopted its current name, Alterity Therapeutics Limited, in April 2019.

alteritytherapeutics.com

Employees: 11
IPO / List date: Mar 28, 2000
HQ: AU

Held by traders on TradeandTell

No one on the platform currently holds ATH.AX.

Super investors & insiders

Institutions holding (13F)

No tracked institution reports a position in ATH.AX as of their last filing.

Insider activity (SEC Form 4)

No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.

Insider activity (SEC Form 4)

Recent trades on TradeandTell

No one on the platform has traded ATH.AX yet.